Drug Profile
Research programme: neurodegenerative disease therapies - Emalex Biosciences
Latest Information Update: 24 Aug 2018
Price :
$50
*
At a glance
- Originator Psyadon Pharmaceuticals
- Class
- Mechanism of Action Glutamate receptor antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Discontinued Amyotrophic lateral sclerosis
Most Recent Events
- 14 Aug 2018 Psyadon Pharmaceuticals has been acquired and merged into Emalex Biosciences
- 13 Nov 2008 Discontinued - Preclinical for Amyotrophic lateral sclerosis in USA (unspecified route)
- 10 Aug 2004 Preclinical trials in Amyotrophic lateral sclerosis in USA (unspecified route)